Gasdermin-mediated pyroptosis confers anticancer immunity

Abstract

Gasdermin (GSDM)-mediated pyroptosis, a form of immunogenic cell death, has emerged as a mechanism capable of conferring anticancer immunity. GSDM activation is central to inducing cancer cell pyroptosis (CCP) and is a crucial link to anticancer immunity. Using a bispecific antibody, we triggered GSDMB-mediated pyroptosis in gastric cancer cells, significantly improving tumor cell eradication and promoting immune cell infiltration and activation in the tumor microenvironment. This innovative strategy presents a highly promising pathway for the targeted activation of GSDM, thereby inducing CCP and ultimately amplifying the effectiveness of cancer immunotherapy. Consequently, this commentary explores the broad-ranging impacts and prospects associated with inducing GSDM-mediated pyroptosis in the context of anticancer immunity, further underscoring the potential challenges and future directions related to the employment of GSDM-mediated pyroptosis in cancer immunotherapy.